Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 30;12:652160. doi: 10.3389/fimmu.2021.652160

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Maes, Mondino, Lasarte, Agirre, Vanderkerken, Prosper and Breckpot

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Examples of increased tumor immunogenicity and modulation of the immune cell constitution in the TME upon treatment with epigenetic compounds. (A) EZH2 inhibition results in increased antigen presentation and T cell activity. (B) HDAC or DNMT inhibition increases antigen presentation and T cell activity while reducing MDSC and M2 macrophages. (C) Bromodomain inhibitors (JQ1) increase antigen presentation and T cell activity while it reduces tumoral PDL1 expression and IDO in the TME. JQ1 also induces a more complete picture of ICD with a type I IFN response, ecto-calreticulin, HMGB1 and ATP release. JQ1 moreover reduces CD47 expression in tumor cells (D) G9a inhibitors and CM-272 induce a type I IFN response due to viral mimicry in tumor cells. CM-272 induces a more complete picture of ICD with a type I IFN response, ecto-calreticulin, HMGB1 and ATP release. IDO, Indoleamine 2,3-dioxygenase.